LinkedIn
icn_podcast Podcasts
View All Upcoming Courses
Specialty
Course Type
Search
Login
Specialty
Aesthetics Cardiology Cataract & Refractive Dermatology General Ophthalmology Glaucoma Neuro-Ophthalmology Oculoplastics Optometry Retina Women's Health View All Courses
Course Type
Evaluation Supplement Multimedia Webinar Podcast In-Person Multi-part Collection
Search
Login
Menu

Cataract Surgery: Discussions on Post-Operative Ocular Inflammation

By: Leon W. Herndon Jr., MD; Sydney L. Tyson, MD, MPH

Begin Course

This course has expired. You can still review the content but course credit is no longer available.

Webinar Credits: 0.5

Despite the routine use of antibiotics, corticosteroids, and nonsteroidal anti-inflammatory (NSAID) agents in postoperative ophthalmic surgical care, there remain issues with drug delivery of these agents. Ongoing education about novel corticosteroids and technologies is warranted to ensure eye care providers can deliver the best patient care possible. All education activities identified in this education design document will be targeted to ophthalmologists and optometrists. The following categories of doctors have been identified as those with the greatest need for this educational intervention: I. Ophthalmologists who perform ophthalmic surgery. II. Ophthalmologists involved in the management of ocular inflammation following ophthalmic surgery. III. Optometrists who comanage patients following cataract surgery.

Expiration Date: Thursday, June 15, 2023
Release Date: June 29, 2020

Supported through an independent educational grant from Ocular Therapeutix.

Learning Objectives

At the completion of this educational activity, you will be better able to:

  • Compare the drug delivery properties of novel sustained-release medications.
  • Identify the issues surrounding patient adherence and compliance with topical medications after ocular surgery.
  • Interpret and explain to patients the latest available treatments and determine which option is best for each patient.
  • Describe how federal regulations on reimbursement affect practices as well as patients being treated for pain and inflammation associated with ophthalmic surgery.

 

 

Accreditation and Designation Statement

Provided by Evolve Medical Education

Accreditation Statement

Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

Evolve designates this enduring. material for a maximum of .5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Sponsored by:

Evolve is an approved COPE Administrator.
This course is COPE approved for .5 hour of CE credit for optometrists.

COPE Course ID: 68467-PH
COPE Activity ID: 119811

 

Participation Method

In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

 

Course Viewing Requirements

Supported Browsers:

Internet Explorer 11 for Windows

Edge (recent versions; Chromium-based) for Windows

Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux

Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux

Safari (recent versions) for Mac OSX, or iOS

Hardware Requirements:

4GB+ RAM

Recommended internet speed 5Mbps+

Faculty and Disclosures

 

 

Leon W. Herndon Jr., MD

Professor of Ophthalmology

Chief of Glaucoma Division

Duke Eye Center

Durham, North Carolina

 

 

Sydney L. Tyson, MD, MPH

President, Eye Associates and SurgiCenter

Vineland, New Jersey

Attending Surgeon, Board of Directors, and Treasurer

Cataract Primary Eye Care Service Ltd.

Wills Eye Hospital

 

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Sydney L. Tyson, MD, MPH and/or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon and Ocular Therapeutix. Grant/Research Support: Glaukos and Ocular Therapeutix.  Speaker’s Bureau: Alcon and Ocular Therapeutix.

Leon W. Herndon, MD, and/or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, New World Medical, Ocular Therapeutix, and Santen.  Grant/Research Support: Glaukos. Stock/Shareholder: Sight Sciences.

The Evolve staff and planners have no financial relationships with commercial interests.

Nisha Mukherjee, MD, peer reviewer, have no financial relationships with commercial interests.

 

Disclaimer

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Ocular Therapeutix.

 

Begin Course